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Abstract 
Background: Canine generalized demodicosis is a common parasitic disease caused by the proliferation of Demodex 
mites. The introduction of isoxazoline class treatments in veterinary dermatology has resulted in apparently effective 
treatment of generalized demodicosis. The objective of this study was to evaluate the effectiveness of fluralaner for 
the treatment of canine generalized demodicosis using real-time PCR for the detection and quantification of Demo-
dex DNA.
Methods: Twenty privately owned dogs with clinical symptoms of generalized demodicosis and deep skin scrapings 
positive for Demodex canis mites were enrolled in the study. Following diagnosis (day 0) each dog was treated with 
fluralaner at the recommended commercial dose for tick and flea treatment (25–56 mg/kg) based on body weight. 
Clinical and mite count assessments, and hair sampling for molecular analyses were performed on days 0, 28, 56, 84 
and 112. Demodex DNA was detected and quantified using real-time PCR.
Results: A single oral dose of fluralaner reduced Demodex mite counts in skin scrapings by an average of 98.9% in all 
dogs by day 28. No mites were recovered from skin scrapings from any treated dog by day 56, at which time the dog 
was considered to be clinically cured, with total hair regrowth. There were significant differences among examined 
dogs in qPCR cycle threshold (Ct) values on days 0, 28, 56, 84 and 112. Demodex DNA levels decreased (increasing 
Ct values) throughout the study. Mite DNA was present on day 112, possibly from dead mites, at values significantly 
lower than in samples taken on days 0, 28 and 56. Based on qPCR testing of diluted samples, the Demodex mite popu-
lation was reduced by approximately 1000-fold on day 112.
Conclusions: Oral administration of fluralaner at the recommended dose to dogs with generalized demodicosis is 
highly effective for reducing Demodex mite populations and resolving clinical signs of generalized demodicosis. The 
presence of mite DNA may indicate that treatment did not kill all Demodex mites.
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Background
Canine generalized demodicosis is a common inflam-
matory parasitic skin disease of dogs associated with the 
proliferation of Demodex mites in hair follicles and seba-
ceous glands [1, 2]. This disease remains one of the most 
difficult treatment challenges in veterinary dermatology 
[3]. Dogs can be affected by three recognized Demodex 
species: D. canis, D. injai and D. cornei [4–6]. There is 
still controversy whether D. cornei is a new species, and 
further studies are required to ascertain the specific sta-
tus of this mite [7]. Demodicosis can be classified as local 
or generalized and adult or juvenile onset depending on 
the extent of the lesions and the age of the affected dog. 
Demodicosis can be considered localized if there are no 
more than four lesions and none larger than 2.5 cm in 
diameter [8]. A definitive diagnosis is established through 
finding numerous adult mites and/or immature forms 
on microscopic examination of deep skin scrapings, hair 
plucking, or acetate tape impressions obtained from 
affected areas. Hair plucking and acetate tape impres-
sions are less useful once treatment is administered and 
only skin scrapings can be used for therapeutic monitor-
ing [1].
Demodicosis therapy is time-consuming and frus-
trating for both dog owners and veterinarians. The only 
products labelled for treatment of generalized demodi-
cosis in most countries are based on either amitraz or a 
combination of imidacloprid and moxidectin. Isoxazoline 
derivatives are a new class of potent ectoparasiticides and 
include fluralaner, afoxolaner, lotilaner and sarolaner [9–
12]. Following their introduction for treating flea and tick 
infestations, they have been evaluated off-label for gen-
eralized demodicosis treatment [13] and several studies 
report that they are effective for this use [7, 12–17]. The 
great advantages of isoxazolines are their easy adminis-
tration and certainty of reaching all body areas [16].
Real-time PCR based on an amplified fragment of the 
chitin synthase gene is a specific and sensitive technique 
to detect Demodex DNA and a useful tool for epidemio-
logical studies on this mite [3, 18]. The goal of this study 
was to monitor the effectiveness of fluralaner treatment 
against canine generalized demodicosis, using real-time 
PCR to detect and quantify Demodex DNA, and to exam-
ine whether the fluralaner is able to reduce the Demodex 
population below the detection limit
Methods
Dogs and sampling procedures
Twenty privately owned dogs with clinical symptoms of 
generalized juvenile demodicosis and multiple positive 
deep skin scrapings for Demodex spp. mites were enrolled 
in this study between January 2016 and November 2017. 
All dogs were admitted to the Teaching Hospital at the 
Faculty of Veterinary Medicine in Belgrade for medical 
consultation and assistance. Relevant data (age, breed, 
gender and clinical signs) on the patients were collected 
and recorded by veterinarians during their clinical exam-
ination. Most dogs (n = 11) were mixed breed, while pure 
breeds included two Doberman Pinschers and one each 
of: Pug, English Bulldog, French Bulldog, Maltese, Kan-
gal, Pitbull and Shar Pei. Their age ranged from 3 months 
to 3 years, with 9 male and 11 female dogs.
On the day of initial diagnosis (day 0) all dogs were 
treated with fluralaner (Bravecto chewable tablets, MSD 
Animal Health, Madison, NJ, USA) at the commercial 
dose (25–56 mg/kg) based on body weight. Enrolled dogs 
were not treated with glucocorticoids, other ectopara-
siticides or macrocyclic lactones for at least one month 
prior to day 0. Clinical assessment, mite counts and hair 
sampling for molecular analyses were performed on days 
0, 28, 56, 84 and 112. Hair re-growth assessment was per-
formed by comparing alopecic areas over the 16-week 
study and was expressed as hair re-growth percentage 
classified as 0–50%, 50–90% or > 90%. Other skin lesions 
(erythema, scales, follicular casts and crusts) were also 
assessed in the same way. Photographs illustrating the 
extent of lesions were taken on each visit to document 
the changes observed.
Deep skin scrapings were taken at each examina-
tion from five affected skin locations, in the direction 
of hair growth using a sharp blade until capillary bleed-
ing occurred. The scraping was transferred to a marked 
microscope slide, mixed with mineral oil and examined 
microscopically at 10× magnification to count adult and 
immature mites. Mite numbers in each scraping were 
recorded separately.
Composite hair samples were obtained for molecu-
lar analysis by gently plucking hairs in the direction of 
growth to include the hair roots. Samples were collected 
from 20 areas including: lip and periocular (four points), 
perinasal, temporal, chin, ventral and dorsal neck, dor-
sum (two points), chest, abdomen (two points), thighs 
(two points) and the interdigital area (four points, one 
on each foot). Hair samples were maintained in phos-
phate-buffered saline and stored at − 20 °C until DNA 
extraction. This sampling method is reliable for detecting 
Demodex spp. on affected dogs [14].
DNA extraction and real‑time PCR
For DNA extraction, samples were centrifuged in a 
microcentrifuge at 13,000× rpm for 30 min. Once the 
supernatant was removed, samples were submerged 
in liquid nitrogen and then disrupted using a homog-
enizer. Isolation was performed using a commercial kit 
(Thermo Scientific GeneJET Genomic DNA Purification 
Kit, cat. no. K0722; Thermo Fisher Scientific, Waltham, 
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Massachusetts, USA) according to the manufacturer’s 
instructions with minor modifications (samples were 
incubated for 24 h with Proteinase K Solution and Diges-
tion Solution).
Real-time PCR [14] reactions were performed (Rotor-
Gene Q 5plex; Qiagen, Hilden, Germany) in a total vol-
ume of 20 μl (FastStart Universal SYBR Green Master; 
Roche Diagnostics GmbH, Mannheim, Germany) using 
0.3 µmol/l of each primer and 4 µl of DNA. The follow-
ing primers were used: D. canis forward, 5′-GAT GAA 
GCG GCG AGT AAT GTT C-3′, reverse, 5′-GAC TCC 
ATC TTT TAC GAT GTC TGA TTT-3′. These amplified 
a 166-bp fragment of the chitin synthase gene. Nuclease-
free water was used as a negative control for the PCR. 
Positive controls were obtained from clinical samples 
that were previously amplified and sequenced to confirm 
Demodex. The thermal cycling profile was as follows: 50 
°C for 2 min and 95 °C for 10 min, followed by 40 cycles 
at 95 °C for 15 s and 60 °C for 1 min.
Statistical analysis
Data were tested for normality using the Kolmogorov-
Smirnov test. Normality was rejected (Kolmogorov-
Smirnov test, P < 0.05) and the Friedmanʼs test with a 
post-hoc test (Dunn’s pairwise test with Bonferroni cor-
rection) were used. Data are presented as median Ct val-
ues with corresponding interquartile range (IQR) (25th 
and 75th percentile). Significant differences were esti-
mated with P < 0.05, P < 0.01, P < 0.001 and P < 0.0001 
significance levels. Statistical analysis was performed 
with GraphPad Prism v.6 (GraphPad, San Diego, CA, 
USA).
Results
All enrolled dogs completed the study following treat-
ment with the recommended fluralaner dose. All dogs ate 
the tablet with no evidence of any post-treatment emesis 
in any dog. No other adverse reactions were observed in 
any treated dog.
Clinical symptom evaluation and mite counts
Significant clinical improvement with a dramatic reduc-
tion in mite numbers in skin samples was seen by day 28 
(Table 1). A single oral dose of fluralaner resulted in an 
average Demodex mite count reduction of 98.9% in all 
dogs on skin scrapings at the first follow-up visit. On day 
56 and on all further examination visits, no mites were 
recovered on skin scrapings from any treated dog. All 
patients have reported on dermatological examination a 
one year after fluralaner therapy, with no clinical signs of 
demodicosis and no mites were found on skin scrapings.
Clinical signs of demodicosis also improved remark-
ably during the first four weeks. Crusts were present on 
the skin of seven dogs and six dogs still had some ery-
thematous patches of alopecia on day 28. On day 56 all 
treated dogs showed a complete clinical cure with total 
hair regrowth (Fig. 1).
PCR results
Results of qPCR analyses are presented as cycle thresh-
old (Ct) values for each sample. There were significant 
differences between Ct values on days 0, 28, 56, 84 and 
112 among examined dogs (Friedmanʼs test, n = 20, χ2 
= 80.0, df = 4, P < 0.0001). Median Ct values with cor-
responding interquartile range (IQR) (25th and 75th 
percentile) are presented for each time point (Table  2). 
Dunn’s pairwise post-hoc test with Bonferroni correction 
revealed significant differences in Ct values between days 
0 and 56 (P = 0.001); 0 and 84 (P < 0.001); 0 and 112 (P < 
0.001); 28 and 84 (P = 0.001); 28 and 112 (P < 0.001); and 
56 and 112 (P = 0.001). Ct values were not significantly 
different between adjacent time points (days 0 and 28, 28 
and 56, 56 and 84, and 84 and 112) (Fig. 2).
Discussion
Fluralaner treatment of dogs with generalized demodi-
cosis, a serious and potentially life-threatening disease, 
resulted in a significant decrease in quantitated Demodex 
DNA. Previously approved treatments require repeated 
applications over long periods of time, with the poten-
tial for adverse side effects [19, 20]. Parasitological heal-
ing is considered to be achieved if two consecutive skin 
scrapings taken at monthly intervals are negative for all 
Demodex life forms, whether dead or alive [21]. In this 
study, a single oral dose of fluralaner resulted in nega-
tive skin scrapings in all treated dogs by day 56, and all 
dogs remained negative on all further skin scrapings. On 
day 112, skin scrapings from all the dogs in this study 
remained negative for Demodex mites (Table 1), despite 
being four-weeks beyond the protection period against 
flea and tick infestation [22].
All dogs enrolled in this study had clinical signs of 
generalized demodicosis at the time of treatment (day 
Table 1 Changes in mite counts and clinical signs in dogs with 
generalized demodicosis following oral treatment with fluralaner
Study day No. of mites
(geometric 
mean)
Efficacy (%) Reduction of clinical 
symptoms and hair 
regrowth (%)
0 496 – –
28 5.6 98.9 50–90
56 0 100 > 90
84 0 100 > 90
112 0 100 > 90
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0) including: erythematous patches, alopecia, scales, 
crusts and follicular casts. The decrease in mite counts 
observed in the skin scrapings was paralleled by a dra-
matic reduction in the extent and severity of the skin 
lesions. Eight weeks after fluralaner treatment all dogs 
were without clinical signs of demodicosis and total 
hair regrowth was observed. Our results are consistent 
with research undertaken by Fourie et al. [7].
The qPCR revealed a decrease in the amounts of 
Demodex spp. DNA (increasing Ct values) through-
out the post-treatment period. Demodex DNA was 
still detectable on day 112 but was significantly lower 
in comparison with samples from days 0, 28 and 56 
(Fig. 1). By using molecular methods to detect Demodex 
DNA, it is theoretically possible to amplify DNA from 
Fig. 1 Multiple photos of a dog with generalized demodicosis showing the clinical condition on a day 0 and b day 56 following fluralaner 
treatment
Table 2 qPCR median cycle threshold (Ct) values with 
interquartile ranges (IQR) for Demodex mite DNA in samples from 
dogs with generalized demodicosis treated with fluralaner on 
day 0, 28, 56, 84 and 112
Sample Median Ct (IQR)
Sampled on day 0 21.3 (18.9–23.1)
Sampled on day 28 23.6 (21.7–24.6)
Sampled on day 56 25.8 (24.2–28.1)
Sampled on day 84 28.2 (26.0–29.8)
Sampled on day 112 30.7 (28.4–31.4)
Undiluted control 23.4 (23.4–23.5)
10× diluted control 26.5 (26.4–26.6)
100× diluted control 29.7 (29.5–30.1)
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dead mites. However, the epidermis of the dog under-
goes continuous renewal with full turnover occurring 
approximately every 21 days [13, 23], so the detection 
of dead mite DNA is unlikely. Throughout the whole 
experiment the quantity of DNA detected by qPCR 
decreased. This reduction proves that the majority of 
the DNA load came from live Demodex. If the DNA of 
all dead Demodex parasites had remained in the skin, 
the decrease in DNA and a consequent increase in Ct 
values throughout the experiment would not be so sig-
nificant. Ct values were continually rising over time 
(Table 2) and by day 112, the median Ct value increased 
by 9.4 cycles in comparison to day 0. Standard serial 
dilutions of a control sample were included in each run 
and their Ct values increased by around 3 cycles in each 
of the following dilutions. Assuming 100% amplifica-
tion efficiency, it can be concluded that the Demodex 
population was reduced between 100 and 1000 times. 
Therefore, Fluralaner at the labelled dose may not have 
completely eliminated the Demodex mites although 
their population was significantly reduced. This is con-
sistent with previous work showing that treatment with 
afoxolaner and fluralaner does not impact Demodex 
populations in normal dogs [13]. It would be of interest 
to monitor dogs for a longer period of time, to deter-
mine Ct values every four weeks and to compare this 
results with the Ct values of asymptomatic dogs that 
never had canine demodicosis.
Conclusions
Oral administration of fluralaner to dogs with general-
ized demodicosis at the recommended dose for treating 
fleas and ticks is highly effective for reducing Demodex 
mite counts and eliminating the clinical signs of disease. 
A single treatment with fluralaner may not completely 
eliminate all mites based on qPCR measurement of mite 
DNA.
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